The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on ...

The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

In transfusion medicine, “wrong blood in tube” is not simply a paperwork issue: a misidentified blood group can lead to a ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...